Lutris Pharma has concluded subject enrolment in its Phase II clinical trial of LUT014, a new B-Raf inhibitor designed for topical application to treat acneiform rash due to epidermal growth factor ...

CHICAGO – Patients with colorectal cancer who had acneiform rash and applied LUT014 gel, an investigational topical BRAF inhibitor, were more likely to experience improvement of their rash compared ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients with advanced colorectal cancer who were treated with an epidermal growth ...

The main signs of COVID-19 are respiratory symptoms, like congestion and a cough. But COVID-19 can also cause skin rashes, dermatologists say. And the coronavirus is just one of many viruses that may ...